Systemic-onset juvenile idiopathic arthritis: The changing life of a rare disease

Swiss Medical Weekly

Volumn 142, Issue MAY, 2012, Pages

  Cimaz, Rolando ^a   Von Scheven, Annette ^b,c   Hofer, Michael ^b,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Cliniques HUG   (Switzerland)

Author keywords

Pediatric rheumatology

Indexed keywords

ACETYLSALICYLIC ACID; CANAKINUMAB; CORTICOSTEROID; DICLOFENAC; ETANERCEPT; IBUPROFEN; INDOMETACIN; METHOTREXATE; NAPROXEN; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; STEROID; THALIDOMIDE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

AMYLOIDOSIS; ANEMIA; CASE REPORT; CERVICAL LYMPH NODE; CHILD; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EMERGENCY WARD; ERYTHEMA; FATIGUE; FEMALE; FEVER; FOOT EDEMA; HAND EDEMA; HOSPITAL ADMISSION; HUMAN; HYPERFERRITINEMIA; INJECTION SITE PAIN; IRRITABILITY; JOINT SWELLING; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL CARE; MEDICAL HISTORY; MUSCULOSKELETAL SYSTEM EXAMINATION; NEUTROPHILIA; PAIN; PATHOGENESIS; PERICARDIAL EFFUSION; POLYARTHRITIS; POOR GENERAL CONDITION; PRESCHOOL CHILD; PROGNOSIS; RARE DISEASE; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTOSIS; WEIGHT REDUCTION; QUALITY OF LIFE; RASH;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD, PRESCHOOL; EXANTHEMA; FEMALE; FEVER; HUMANS; INDOMETHACIN; METHOTREXATE; QUALITY OF LIFE; STEROIDS;

EID: 84863501920     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13582     Document Type: Review

References (51)

1. Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60 49.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, edmonton, 2001. J Rheumatol. 2004;31:390-2. (Pubitemid 38160763)
3. Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998;351:969-73. (Pubitemid 28138480)
4. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol. 1998;12:245-71. (Pubitemid 28492906)
5. Woo P. Systemic juvenile idiopathic arthritis: Diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2:28-34. (Pubitemid 43153646)
6. Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: Data from the Pennsylvania systemic onset juvenile arthritis registry (Pasojar). J Rheumatol. 2008;35:343-8. (Pubitemid 351281158)
7. Feldman BM, Birdi N, Boone JE, Dent PB, Duffy CM, Ellsworth JE, et al. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr. 1996;129:513-8. (Pubitemid 27490787)
8. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133-8. (Pubitemid 46774861)
9. Calabro JJ, Marchesano JM. Rash associated with juvenile rheumatoid arthritis. J Pediatr. 1968;72:611-9.
10. Schaller J, Wedgwood RJ. Pruritus associated with the rash of juvenile rheumatoid arthritis. Pediatrics. 1970;45:296-8.
11. Goldenberg J, Ferraz MB, Pessoa AP, Fonseca AS, Carvalho AC, Hilario MO, Atra E. Symptomatic cardiac involvement in juvenile rheumatoid arthritis. Int J Cardiol. 1992;34:57-62.
12. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: Possible relationship to drugs or infection. J Pediatr. 1985;106:561-6. (Pubitemid 15080542)
13. Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764-8.
14. Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129:630-2. (Pubitemid 27498267)
15. David J. Amyloidosis in juvenile chronic arthritis. Clin Exp Rheumatol. 1991;9:73-8.
16. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology. (Oxford) 2005;44:1350-3. (Pubitemid 41631856)
17. Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis - from pathophysiology to treatment. Rheumatology. (Oxford) 2008;47:121-5. (Pubitemid 351168217)
18. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (il-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479-86. (Pubitemid 40664091)
19. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19:424-30.
20. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, et al. S100a12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58:3924-31.
21. Vastert SJ, Kuis W, Grom AA. Systemic JIA: New developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23:655-64.
22. Belot A, Bader-Meunier B, Niaudet P, Salomon R, Prieur AM, Noel LH, et al. ANCA-Associated Glomerulonephritis in Systemic-Onset Juvenile Idiopathic Arthritis. Am J Kidney Dis. 2012;59:439-43.
23. Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:883-91.
24. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol. 1998;25:203-7.
25. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158-63.
26. Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 2004;50:1935-8. (Pubitemid 38725105)
27. Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in japanese patients with adult still's disease. Association with chronic articular disease. Rheumatology. (Oxford) 2001;40:1398-404.
28. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: Preliminary experience in France. Ann Rheum Dis. 2008;67:302-8. (Pubitemid 351281262)
29. Woo P. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Ann Rheum Dis. 2008;67:281-2. (Pubitemid 351281258)
30. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2071-5. (Pubitemid 39336738)
31. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747-54.
32. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 2007;204:2131-44. (Pubitemid 47360874)
33. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505-15. (Pubitemid 351705940)
34. Prieur AM, Roux-Lombard P, Dayer JM. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rhum Engl Ed. 1996;63:163-70. (Pubitemid 26109965)
35. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998-1006. (Pubitemid 351389534)
36. Lotito AP, Campa A, Silva CA, Kiss MH, Mello SB. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J Rheumatol. 2007;34:823-30. (Pubitemid 46641392)
37. Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev. 2011;10:482-9.
38. Jelusic M, Lukic IK, Tambic-Bukovac L, Dubravcic K, Malcic I, Rudan I, et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin Rheumatol. 2007;26:1332-4. (Pubitemid 47034191)
39. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology. (Oxford) 2010;49:1645-53.
40. de Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2782-93.
41. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol. 2009;36:1078-82.
42. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093-101. (Pubitemid 36418252)
43. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32:935-42. (Pubitemid 40676507)
44. Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr. 2004;145:856-7. (Pubitemid 39586632)
45. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306:2340-7.
46. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:545-55.
47. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557-67.
48. Gillespie J, Mathews R, McDermott MF. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). J Inflamm Res. 2010;3:1-8.
49. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in caucasian children with severe systemic juvenile idiopathic arthritis: Proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281-1288.
50. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken) 2011;63:465-82.
51. Dewitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. 2012 Jan 30 [Epub ahead of print].